Jilin Aodong Pharmaceutical Group Co., Ltd. (SHE:000623)

SHE:000623 Revenue

Jilin Aodong Pharmaceutical Group had revenue of 512.28M CNY in the quarter ending September 30, 2026, a decrease of -0.32%. This brings the company's total for the last twelve months to 2.24B, down -4.41% year-over-year. In the year 2025, Jilin Aodong Pharmaceutical Group had annual revenue of 2.34B, down -10.55%. That makes Jilin Aodong Pharmaceutical Group the 13,730th largest company in the world by revenue and 2,435th in China.

• Revenue (ttm): 2.24B
• Revenue Growth: -4.41%
• P/S Ratio: 8.82
• Revenue / Employee: 443.20K
• Employees: 5,050
• Market Cap: 19.74B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Medicine 1.80B 71.3%
• Chain drugstore wholesale and retail 383.29M 15.2%
• Food 199.70M 7.9%
• Other Segment 140.82M 5.6%
• Group Investment Division 1.65M 0.1%

By Geography

Chart

• North East China 843.00M 36.1%
• East China 526.55M 22.5%
• Southwest China 311.17M 13.3%
• South China 298.52M 12.8%
• North China 205.79M 8.8%
• Northwest China 150.16M 6.4%

Fiscal year ended Dec 31, 2025 See the full SHE:000623 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	2.34B	-275.38M	-10.55%
Dec 31, 2024	2.61B	-838.55M	-24.31%
Dec 31, 2023	3.45B	580.91M	20.25%
Jan 1, 2023	2.87B	564.45M	24.50%
Jan 1, 2022	2.30B	52.11M	2.31%

Data Source: S&P Global Market Intelligence Last updated: Oct 29, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 31, 2026

Data Sources Report a data error